BMA three-lens brief
Evidence-based stock research on BMA. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
50-day MA below 200-day MA (death-cross regime); price below both. · Trading at 2% of its 52-week range — deep in the lower band.
- Trading at 2% of its 52-week range — deep in the lower band.
- 50-day MA below 200-day MA (death-cross regime); price below both.
- Underperforming SPY by 14.1pp over 30 days.
- P/E of 11.7 — trading at a value multiple.
- Analyst mean target $102.99 — 80% above current (9 analysts).
BMA closed at $57.23 (-1.04%) as of 2026-11-12. Market cap: $3.66B. P/E (trailing) 11.7. Price is below the 50-day MA and below the 200-day MA. Positives: p/E of 11.7 — trading at a value multiple.; analyst mean target $102.99 — 80% above current (9 analysts).. Concerns: trading at 2% of its 52-week range — deep in the lower band.; 50-day MA below 200-day MA (death-cross regime); price below both.. Last quarter: Revenue $1.25T, net income $206.63B. Watching for: 2026-11-25 earnings release (13 days out).
Why three lenses on BMA, not one.
A single reasoning model has blind spots it doesn’t know about. We examine BMA across Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://www.clearpathinvest.app/embed/BMA" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath BMA brief"></iframe>